Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 48 (2), 161-168

Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study

Affiliations

Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study

Geetanjali R Kamath et al. Pancreas.

Abstract

Objective: This study aimed to describe the relative and excess risk of pancreatic neuroendocrine tumor (NET) at least 6 months after the first primary cancer (FPC) among the US population.

Methods: Surveillance, Epidemiology, and End-Results Program data were analyzed for patients diagnosed as having FPC from 2000 to 2015 (n = 4,008,092). Standardized incidence ratios, excess risk, and average time to diagnosis of a second primary pancreatic NET were reported by FPC site, stratified by sex and receipt of radiotherapy and chemotherapy.

Results: Risk of pancreatic NET was significantly higher after FPC at any site, any solid tumor (standardized incidence ratios, 1.3; 95% confidence interval, 1.2-1.5), pancreas, thymus, small intestine, liver, stomach, kidney, lung, and female breast. Excess incidence of pancreatic NET was highest among those with FPC (especially NET) of the pancreas, bladder, thymus, and female breast; those who received radiotherapy/chemotherapy for bladder, melanoma, and stomach cancers; and those who received chemotherapy for uterine, cervical, prostate, and other genital cancers. Time to diagnosis was shortest after pancreatic, liver, lung, and stomach cancer.

Conclusions: Cancer survivors have increased risk and excess incidence of primary pancreatic NET compared with the population, particularly for certain primary sites. High-risk patients should receive regular follow-up screenings, counseling to reduce carcinogen exposure, and lifestyle interventions.

Conflict of interest statement

Conflict of interest disclosure: The authors declare no conflict of interest.

Figures

FIGURE 1.
FIGURE 1.
Excess risk of second primary pancreatic NET by site of first primary cancer and radiotherapy treatment (per 1000 patients)
FIGURE 2.
FIGURE 2.
Excess risk of second primary pancreatic NET by site of first primary cancer and chemotherapy treatment (per 1000 patients)

Similar articles

See all similar articles

Publication types

MeSH terms

Feedback